Immunocore Holdings plc
IMCR · Nasdaq · United Kingdom
Share price · IMCR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IMCR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+9.1%
- 29 Oct 2026-4.1%
- 20 Oct 2026+9.2%
Nothing announced by IMCR that day or the session before.
- 22 Jul 2026+3.1%
Nothing announced by IMCR that day or the session before.
- 30 Jun 2026+4.4%
Nothing announced by IMCR that day or the session before.
- 3 Jun 2026-3.1%
Nothing announced by IMCR that day or the session before.
- 8 May 2026-3.4%
Nothing announced by IMCR that day or the session before.
- 6 May 2026+6.6%
- 21 Apr 2026-6.2%
Nothing announced by IMCR that day or the session before.
- 6 Apr 2026+3.6%
Nothing announced by IMCR that day or the session before.
Share of unusual movement by asset
For each asset, the share of IMCR's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
tebentafusp-tebn(KIMMTRAK) | Approved | gp100-HLA-A*02:01 x CD3Protein / enzyme therapeutic | Uveal MelanomaMelanoma Unresectable or Metastatic Uveal Melanoma |
| Phase 3 | PRAME antigen presented on HLA-A*02:01Protein / enzyme therapeutic | Melanoma Cutaneous Melanoma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $102M | $75M | $512M+ $389M short-term inv. | $14M$20M operating cash flow | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $116M | $74M | $485M+ $395M short-term inv. | $0.8M$16M operating cash flow | report ↗ |
| 2026-Q1 | $107M | $61M | $453M+ $392M short-term inv. | —-$14M operating cash flow | report ↗ |
| 2025-Q3 | $104M | $71M | $498M+ $394M short-term inv. | $0.2M-$4.5M operating cash flow | report ↗ |
| 2025-Q2 | $98M | $69M | $488M+ $395M short-term inv. | $10M$26M operating cash flow | report ↗ |
| 2025-Q1 | $94M | $56M | $477M+ $360M short-term inv. | —$0.4M operating cash flow | report ↗ |
| 2024-Q3 | $80M | $53M | $538M+ $364M short-term inv. | —$21M operating cash flow | report ↗ |
| 2024-Q2 | $75M | $51M | $505M+ $355M short-term inv. | $12M$23M operating cash flow | report ↗ |
| 2024-Q1 | $71M | $57M | $833M | $24M-$4.6M operating cash flow | report ↗ |
| 2023-Q3 | — | $43M | $444M | —$10M operating cash flow | report ↗ |
| 2023-Q2 | — | $38M | $432M | $17M$0.1M operating cash flow | report ↗ |
| 2023-Q1 | — | $37M | $418M | $19M$11M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $400M | $275M | $468M+ $396M short-term inv. | $8.9M-$11M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $310M | $222M | $456M+ $365M short-term inv. | $13M$26M operating cash flow | report ↗ |
| 2023-FY | $239M | $164M | $443M+ $0 short-term inv. | $14M$2.9M operating cash flow | report ↗ |
| 2022-FY | $141M | $102M | $402M | $13M-$49M operating cash flow | report ↗ |
| 2021-FY | $4.1M | $100M | $321M | $45M-$143M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 10 sales ($5.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-05-27 | Bell John Irving · director | Award / grant (derivative) | 27,492 | — | — | Form 4 |
| 2026-05-27 | Herbst Roy Steven · director | Award / grant (derivative) | 27,492 | — | — | Form 4 |
| 2026-05-27 | Kaul Siddharth · director | Award / grant (derivative) | 27,492 | — | — | Form 4 |
| 2026-05-27 | Pao William · director | Award / grant (derivative) | 27,492 | — | — | Form 4 |
| 2026-05-27 | Peterson Kristine · director | Award / grant (derivative) | 27,492 | — | — | Form 4 |
| 2026-05-27 | Ratcliffe Peter John · director | Award / grant (derivative) | 27,492 | — | — | Form 4 |
| 2026-02-18 | Berman David M · HEAD OF R&D | Open-market sale | 5,965 | $32.35 | $193K | Form 4 |
| 2026-02-18 | St Leger Tina Amber · CHIEF HR OFFICER | Open-market sale | 1,000 | $32.35 | $32K | Form 4 |